Recent News

Elmiron Update: Warnings Changed to Include Risk of Eye Damage

On June 16th, 2020,  the Food and Drug Administration (FDA) announced labeling changes to Elmiron, a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss the potential dangers to consumers taking Elmiron, and how to seek legal representation…

Read More...

Elmiron Linked to Vision Loss

Elmiron is a popular anticoagulant that is commonly prescribed to treat bladder pain caused by interstitial cystitis and osteoarthritis. Recently, Elmiron has been linked to the increased risk of pigmentary maculopathy and other forms of vision loss and damage. The pharmaceutical liability attorneys at Peter Angelos Law Law are actively investigating cases regarding the use…

Read More...

COVID-19 Business Interruption Coverage Denial Investigation

The global impacts of the COVID-19 pandemic continue to result in economic losses to businesses and individuals around the world. Additionally, governments are mandating that individuals quarantine themselves to contain the spread of the outbreak. These actions have resulted in changes in consumer behavior, and in turn, negatively impact many businesses. Here, the attorneys at…

Read More...

Continuous Surgical Staple Recalls Lead to Increased Litigation

For many years, defective surgical staples have caused irreparable harm to patients, but these dangers remained hidden. In 2019, the Food and Drug Administration (FDA) acknowledged that thousands of surgical staple malfunction reports were hidden from the public. Here, the medical device litigation team at Peter Angelos Law discusses the various companies under scrutiny for…

Read More...

FDA Requests Removal of Zantac From the Market Immediately

On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss…

Read More...

Singulair – FDA Strengthens Warning of Serious Mood and Behavorial Side Effects, Including Suicidal Thoughts, Associated with Common Allergy Medications

After convening a panel of outside experts, the FDA determined that the asthma and allergy medication montelukast, available as brand-name Singulair or in generic form, should include a Boxed Warning to ensure that health care professionals and patients are aware of the potential for severe mood-related side effects, particularly in children. Singulair, Along with Generic…

Read More...

FDA Requests Withdrawal of Weight-Loss Drug

On February 13th, the Food and Drug Administration (FDA) requested that drug manufacturer Eisai Inc. remove diet drugs Belviq and Belviq XR from the market after a clinical trial showed an increased occurrence of cancer in patients taking Belviq. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss the FDA’s decision to request this…

Read More...

The FDA Issues Warning Letter to Vivitrol Manufacturer Alkermes for Omitting Risk Information

In December 2019, the Food and Drug Administration (FDA) sent a warning letter to Alkermes, the manufacturers of the drug Vivitrol, for a print advertisement that misled consumers by omitting important risk information. By failing to admit the potentially fatal consequences of opioid intoxication, the safety of Vivitrol is now being called into question. Here,…

Read More...

The FDA Requests Allergan Voluntarily Recall

In August 2019, the Food and Drug Administration (FDA) requested that Allergan recall its BIOCELL textured breast implants and tissue expanders due to an increased risk of cancer among implant patients. Here, the product and medical device  liability litigation attorneys at Peter Angelos Law discuss the connection between Allergan’s BIOCELL products and the increased risk…

Read More...

Continuation of Monsanto Dicamba Litigation Updates

In August 2019, environmentally conscious public-interest organizations filed a lawsuit against the U.S. Environmental Protection Agency and agrochemical company, Monsanto, after the approval of a pesticide meant for use on soybean and cotton plants. Here, the environmental litigation attorneys at Peter Angelos Law discuss the controversy surrounding the damaging dicamba pesticide and how the EPA’s…

Read More...